X
Lilly keeps ahead of Blueprint with swift FDA review for selpercatinib
https://pharmaphorum.com/news/lilly-keeps-ahead-of-blueprint-with-swift-fda-review-for-selpercatinib/
novel targeted cancer treatments
Bayer and MD Anderson collaborate on novel targeted cancer treatments
Bayer and the University of Texas MD Anderson Cancer Center have signed a five-year collaboration agreement to accelerate the development of novel targeted treatments for cancer.